Trial Profile
A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 30 Jan 2009 Actual patient numbers (71) added as reported by ClinicalTrials.gov.
- 30 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.